Republic of the Philippines

CEBU NORMAL UNIVERSITY

Osmeña Blvd., Cebu City, 6000, Philippines

College of Nursing
Telephone No.: (+63 32) 254 4837
Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph

DRUG STUDY
Patient’s Initials: H.T.B.__ Date of Admission: October 19, 2021 Diagnosis: DM Type II, HHNKS, Gangrenous Right Foot secondary to Uncontrolled DM Type 2
Age: 63 years old Height/Weight: 5’4”/90 kg_____________________ Clinical Intervention: BKA, right foot
Sex: Male ______Ward: Medical Pavilion Bed No.: 6 Name of Physician: Dr. Camay Moscuvado

Drug Information Classification Mechanism of Action Indication Contraindications Side Effects Nursing Responsibilities
Generic Name: Pharmacologic Pharmacodynamics or General Indication/s: Contraindicated in: (per system preferably) Before Drug Administration:
Gliclazide Classification: Mechanism of Action:  Control of blood sugar  Hypersensitivity - Assess patient if s/he has allergies
Sulfonylureas Gliclazide selectively binds to in type 2 diabetes  Unstable diabetes ENDO: to medication.
Trade Name: sulfonylurea receptors (SUR-1) mellitus when control  Type 1 diabetes hypoglycemia, - Explain to the patient that this
Diamicron MR Therapeutic on the surface of the pancreatic of diet and exercise mellitus dizziness, weakness, medication does not cure diabetes
Classification: beta-cells. It was shown to fails or when insulin  Diabetic drowsiness, and must be used in conjunction
Minimum Dose: Antidiabetics provide cardiovascular is not an option headache, sweating, with the prescribed diet, exercise
ketoacidosis
80 mg/day (tablets) protection as it does not bind to  Requires some  Diabetic coma or nervousness, shaking, regimen, to prevent
30 mg/day Pregnancy sulfonylurea receptors (SUR- tingling of the hands hypoglycemic and hyperglycemic
pancreatic function pre-coma
(modified-release Category: 2A) in the heart. This binding or feet, hunger, fast events.
 Severe hepatic or - Obtain baseline vital signs.
tablets) Not applicable effectively closes the K+ ion Patient’s Indication: renal disease heartbeat.
channels. This decreases the To control hyperglycemia  Alcohol or During Drug Administration:
Maximum Dose: efflux of potassium from the or high blood sugar levels alcohol- GI: abdominal pain,
320 mg/day cell which leads to the diarrhea, dyspepsia, - Administer once daily in the
of the patient since he has containing evening.
(tablets) depolarization of the cell. This Type II Diabetes Mellitus medications increased liver
- This is best taken with meals. Try
120 mg/day causes voltage dependent Ca++ enzymes, nausea,
to take this medication at the
(modified-release ion channels to open increasing vomiting
Precautions: same time(s) each day.
tablets) the Ca++ influx. The calcium
 Liver and kidney
can then binds to and activate DERM:
problems After Drug Administration:
Patient’s Dose: calmodulin which in turn leads photosensitivity,
 Glucose 6- - Advice patient to report any
80mg to exocystosis of insulin rashes, itching, easy
phosphate adverse effects (e.g., weight gain,
vesicles leading to insulin bruising or bleeding swelling of the ankles,
release. dehydrogenase
Route: drowsiness, shortness of breath,

Certification Date: 1 February 2021

Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 1 of 4
check and type the registration number)

Registration No. 52Q18778

 Republic of the Philippines
CEBU NORMAL UNIVERSITY
Osmeña Blvd., Cebu City, 6000, Philippines

College of Nursing
Telephone No.: (+63 32) 254 4837
Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph

PO deficiency muscle cramps, weakness, sore

Pharmacokinetics: (increased risk of throat, rash, or unusual bleeding
Frequency: ONSET: hemolytic anemia) or bruising) occur.
HS/ at bedtime Unknown  Infection, stress, - In case of hypoglycemia, drink a
or changes in diet glass of orange juice or non-diet
Availability/Form PEAK: (alter soda or eat a piece of candy to
Tablets (80 mg); 4-6 hours (blood levels) requirements for raise your blood sugar level
Modified-release control or blood quickly. Report the incident to
tablets (30 mg, 60 DURATION: sugar or require your doctor.
mg) 12-24 hours - Instruct the patient to take
use of insulin)
medications as directed at the
 Impaired thyroid,
same time every day.
Content: ABSORPTION pituitary, or
- If you miss a dose, take it as soon
80mg of gliclazide, Well absorbed following oral adrenal function as remembered; do not take it if it
lactose administration (97%)  Malnutrition, high is near the time for the next dose,
monohydrate, fever, prolonged instead, skip the missed dose and
pregelatinised DISTRIBUTION nausea, or resume your usual dosing
maize starch, Unknown vomiting schedule. Do not "double-up" the
colloidal anhydrous Protein binding: 95% dose to catch up.
silica, magnesium Interactions: - Instruct patient to avoid
stearate and METABOLISM and  sulfonamide prolonged sun exposure. Wear
purified talc EXCRETION antibiotics, blood protective clothing and use an
Extensively metabolized, thinners, effective sunscreen when
metabolites are mostly antidepressants, outdoors.
eliminated (60-70%) in urine, aspirin, - Assess for drug effectiveness.
10-20% in feces; <1% excreted propranolol, - Avoid ingestion of alcohol while
unchanged in urine. rifampin, taking this drug because
phenylbutazone, intolerance may occur resulting in
HALF-LIFE disopyramide, flushing, giddiness, nausea, rapid
Tablets: 10.4 hours probenecid, heart rate.
Modified release tablets: 16 hrs. clofibrate, water

Certification Date: 1 February 2021

Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 2 of 4
check and type the registration number)

Registration No. 52Q18778

 Republic of the Philippines
CEBU NORMAL UNIVERSITY
Osmeña Blvd., Cebu City, 6000, Philippines

College of Nursing
Telephone No.: (+63 32) 254 4837
Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph

pills, steroids, oral

contraceptives,
cimetidine
 Avoid ingestion
of alcohol.

References:
Jones & Bartlett Learning. (2019). 2020 Nurse’s Drug Handbook (19th ed.). Jones & Bartlett Learning.
Lippincott Williams & Wilkins. (Producer). (2013). Nursing 2013 Drug Handbook. Philadelphia, Pa.: Lippincott, Williams & Wilkins
Schull, P. D. (2013). McGraw-Hill nurses drug handbook. New York: McGraw-Hill Medical.
Vallerand, A., Sanoski, C., & Deglin, J. (2017). Drug Guide for Nurses. 15th Ed. FA Davis Company: Philadelphia

Certification Date: 1 February 2021

Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 3 of 4
check and type the registration number)

Registration No. 52Q18778

 Republic of the Philippines
CEBu NORMAL UNIvERSITy
Osmeña Blvd., Cebu City, 6000, Philippines

College of Nursing
Telephone No.: (+63 32) 254 4837
Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph

PRODUCT ASSESSMENT RUBRICS FOR DRUG STUDY

Student Name: ROSALES, GWYN A. Year/Section: Date: Score: /30

Directions: Please select the appropriate rating using the following descriptions.

Element Very Satisfacto Needs Comments

Satisfactory ry Improvement
Drug ☐ Accurately presented all of the patient and drug ☐ Accurately presented most of the patient and ☐ Accurately presented some of the patient and
Informati information (name [brand & generic], dosage drug information related to the case. 1 missing drug information related to the case. 2 or more
on (10%) [patient’s dose; min. & max], frequency, route, information or error noted. [2] missing information or errors noted. [1]
availability, contents) related to the case. [3]
Classificati ☐ Accurately presented the classification ☐ Accurately presented the classification ☐ Inaccurately presented the classification
on (therapeutic and pharmacologic) related to the related to the drug but with 1 irrelevant related to the drug. Classification is not relevant to
(10%) drug. [3] information or error noted. [2] the drug. [1]
☐ Accurately presented the indication/s (general ☐ Accurately presented the indication/s related ☐ Inaccurately presented the indication/s related
Indication
& patient- specific) related to the drug. [3] to the drug but with 1 irrelevant information or to the drug. Indication is not relevant to the drug.
(10%)
error noted. [2] [1]
Mechanism Accurately ☐ presented the ☐ Accurately presented the mechanism of ☐ Inaccurately presented the mechanism of action
of Action mechanism of action action of the drug but with 1 irrelevant of the drug. Mechanism of action is not relevant to
(10%)
(pharmacokinetics, pharmacodynamics) of the information or error noted. [2] the drug. [1]
drug. [3]
☐ Accurately presented all of the common ☐ Accurately presented most of the common ☐ Accurately presented some of the common
Contraindicat
contraindications related to the drug. [3] contraindications related to the drug. 1 missing contraindications related to the drug. 2 or more
ion (10%)
information or error noted. [2] missing information or errors noted. [1]
Side ☐ Accurately presented all of the common side ☐ Accurately presented most of the common ☐ Accurately presented some of the common side
Effects effects related to the drug. [3] side effects related to the drug. 1-2 missing effects related to the drug. 3 or more missing
(10%)
information or errors noted. [2] information or errors noted. [1]

Certification Date: 1 February 2021

Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 4 of 4
check and type the registration number)

Registration No. 52Q18778

 Republic of the Philippines
CEBu NORMAL UNIvERSITy
Osmeña Blvd., Cebu City, 6000, Philippines

College of Nursing
Telephone No.: (+63 32) 254 4837
Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph

Nursing ☐ Accurately presented all of the common ☐ Accurately presented most of the ☐ Accurately presented some of the
Responsibili nursing responsibilities (before, during, and after) common nursing common nursing
ties (30%) related to the drug. [9] responsibilities related to the drug. 1-2 missing responsibilities related to the drug. 3 or more
information or errors noted. [7] missing information or errors noted. [3]
☐ Presented at least 2 sources that are updated ☐ Presented only one source that is updated ☐ No source was presented. Sources are not
Referenc
(within 5 years), relevant, and credible. [3] (within 5 years), relevant, and credible. Other updated (more than 5 years), relevant, and credible.
es
sources are not updated, credible or relevant. [2] [1]
(10%)
Sub-score = = =

Evaluated by:

Signature over Printed Name of Clinical Instructor

Certification Date: 1 February 2021

Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 5 of 4
check and type the registration number)

Registration No. 52Q18778